PROLIFENCT05345587
Quality of Life and Economic Repercussions of Combining Proactive Medication Assessment and Electronic Monitoring of Toxicities in Subjects Undergoing Oral Cancer Therapy
StatusCompleted
PhaseNot applicable
Primary completion
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 6 versions: 6 with changes below. See every version on ClinicalTrials.gov ↗
Notable Primary completion date changed from estimate of Oct 2025 to Oct 7, 2026 Show 5 more changesShow less
- Eligibility criteria expanded, about 15 words
- Trial status changed: Unknown → Completed
- Final enrollment: 152 participants (planned 196)
- Secondary endpoints: details revised at 12 of 35 entries
- Site details revised at 6 of 6 sites
- Minor Changed Registry marked status Unknown; last known: Recruiting
- Notable Primary completion date: Oct 2024 to Oct 2025
- Study sites: 4 to 6
- Study completion date: Oct 2025 to Oct 2026
- Notable Primary completion date: Oct 2023 to Oct 2024
- Study completion date: Oct 2023 to Oct 2025
- Notable Enrollment target: 300 to 196
- Eligibility criteria expanded, about 6 words
- Study sites: 3 to 4
- Secondary endpoints: 42 to 35
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date changed from estimate of Apr 2022 to Sep 16, 2022
- Site details revised at 3 of 3 sites
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Time until decrease in quality of life by 5-points between groups
Timeframe: End of follow-up maximum 18 months
Secondary (10)
Time until progression of cancer between groups
Patient satisfaction with their treatment between groups
Quality of life adjusted years between groups
Cost of care between groups
Toxicity experienced during treatment between groups
Show 5 moreShow less
Relative Dose Intensity between groups
Budget Impact Analysis
Rate of prescription changes since initiation of oral therapy (whether change in usual treatment and oral therapy).
Medication observance
Usability of the Thess monitoring patient interface for the collection of Patient Reported Outcomes
Arms and interventions
Prolife groupExperimental
scheduled consultation with the hospital clinical pharmacist, therapeutic follow-up and collection of clinical information by the patient via the THESS monitoring system
Standard careNo intervention
Other: THESS monitoring
Sites
6 sites in 1 country